Featured Publications
Sex and Gender Differences in Tuberculosis Pathogenesis and Treatment Outcomes
Dabitao D, Bishai WR. Sex and Gender Differences in Tuberculosis Pathogenesis and Treatment Outcomes. Curr Top Microbiol Immunol. 2023;441:139-183. doi: 10.1007/978-3-031-35139-6_6. PMID: 37695428.
Perceived stigma among people with TB and household contacts
Machavariani E, Nonyane BAS, Lebina L, Mmolawa L, West NS, Dowdy DW, Martinson N, Ahmad B, Hanrahan CF. Perceived stigma among people with TB and ...
Determining cost and placement decisions for moderate complexity NAATs for tuberculosis drug susceptibility testing
Malhotra A, Thompson R, De Vos M, David A, Schumacher S, Sohn H. Determining cost and placement decisions for moderate complexity NAATs for tuberculosis drug ...
Timing of maternal isoniazid preventive therapy on tuberculosis infection among infants exposed to HIV in low-income and middle-income settings: a secondary analysis of the TB APPRISE trial
Gupta A, Singh P, Aaron L, Montepiedra G, Chipato T, Stranix-Chibanda L, Chanaiwa V, Vhembo T, Mutambanengwe M, Masheto G, Raesi M, Bradford S, Golner ...
Undiagnosed Pulmonary Tuberculosis (TB) and Coronavirus Disease 2019 (COVID-19) in Adults Dying at Home in a High-TB-Burden Setting, Before and During Pandemic COVID-19: An Autopsy Study
Sabet N, Omar T, Milovanovic M, Magajane T, Mosala M, Moloantoa T, Kato-Kalule N, Semedo LV, Swanepoel F, Wallis C, Abraham P, Lebina L, Variava ...
Comparative immune responses to Mycobacterium tuberculosis in people with latent infection or sterilizing protection
Jalbert E, Liu C, Mave V, Lang N, Kagal A, Valvi C, Paradkar M, Gupte N, Lokhande R, Bharadwaj R, Kulkarni V, Gupta A, Weinberg ...
Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs
Ernest JP, Ni Goh JJ, Strydom N, Wang Q, van Wijk RC, Zhang N, Deitchman A, Nuermberger E, Savic RM. Translational predictions of phase 2a ...
Pragmatic cluster-randomized trial of home-based preventive treatment for TB in Ethiopia and South Africa (CHIP-TB)
Malhotra A, Nonyane BAS, Shirey E, Mulder C, Hippner P, Mulatu F, Ratshinanga A, Mitiku P, Cohn S, Conradie G, Chihota V, Chaisson RE, Churchyard ...
Using Dynamic Oral Dosing of Rifapentine and Rifabutin to Simulate Exposure Profiles of Long-Acting Formulations in a Mouse Model of Tuberculosis Preventive Therapy
Chang YS, Li SY, Pertinez H, Betoudji F, Lee J, Rannard SP, Owen A, Nuermberger EL, Ammerman NC.
Structure-directed identification of pyridine-2-methylamine derivatives as MmpL3 inhibitors for use as antitubercular agents
Wen Y, Lun S, Jiao Y, Zhang W, Liu T, Yang F, Tang J, Bishai WR, Yu LF.
Effect of the relationship between anaemia and systemic inflammation on the risk of incident tuberculosis and death in people with advanced HIV: a sub-analysis of the REMEMBER trial
Araújo-Pereira M, Krishnan S, Salgame P, Manabe YC, Hosseinipour MC, Bisson G, Severe DP, Rouzier V, Leong S, Mave V, Sawe FK, Siika AM, Kanyama ...
Understanding patient-level costs of weekly isoniazid-rifapentine (3HP) among people living with HIV in Uganda
Sung J, Musinguzi A, Kadota JL, Baik Y, Nabunje J, Welishe F, Bishop O, Berger CA, Katahoire A, Nakitende A, Nakimuli J, Akello L, Kasidi ...
Higher yield using an event-based vs. door-to-door approach for active case-finding for TB
Malhotra A, Mukiibi J, Kitonsa PJ, Nalutaaya A, Kamoga CE, Robsky KO, Isooba D, Nantale M, Nakasolya O, Kayondo F, Mukiibi M, Kiyonga R, Dowdy ...
Viral suppression among adults with HIV receiving routine dolutegravir-based antiretroviral therapy and 3 months weekly isoniazid-rifapentine
Chaisson LH, Semitala FC, Nangobi F, Steinmetz S, Marquez C, Armstrong DT, Opira B, Kamya MR, Phillips PPJ, Dowdy DW, Yoon C.
QuantiFERON Supernatant-Based Host Biomarkers Predicting Progression to Active Tuberculosis Disease among Household Contacts of Tuberculosis Patients
Daniel EA, Thiruvengadam K, Rajamanickam A, Chandrasekaran P, Pattabiraman S, Bhanu B, Sivaprakasam A, Paradkar M, Kulkarni V, Karyakarte R, Shivakumar SVBY, Mave V, Gupta ...
Mycobacterium tuberculosis disease associates with higher HIV-1-specific antibody responses
Adeoye B, Nakiyingi L, Moreau Y, Nankya E, Olson AJ, Zhang M, Jacobson KR, Gupta A, Manabe YC, Hosseinipour MC, Kumwenda J, Sagar M.
A multi-center, prospective cohort study of whole blood gene expression in the tuberculosis-diabetes interaction
Queiroz ATL, Vinhaes CL, Fukutani ER, Gupte AN, Kumar NP, Fukutani KF, Arriaga MB, Sterling TR, Babu S, Gaikwad S, Karyakarte R, Mave V, Paradhkar ...
Editorial: Broadening our understanding of the impact of infections on the developing central nervous system – from basic to clinical sciences
Travassos MA, Rohlwink UK, Tucker EW.
Adjunctive Integrated Stress Response Inhibition Accelerates Tuberculosis Clearance in Mice
Krug S, Prasad P, Xiao S, Lun S, Ruiz-Bedoya CA, Klunk M, Ordonez AA, Jain SK, Srikrishna G, Kramnik I, Bishai WR.
Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model
Li SY, Converse PJ, Betoudji F, Lee J, Mdluli K, Upton A, Fotouhi N, Nuermberger EL.
Do chest x-ray-positive, sputum-negative individuals warrant more attention during tuberculosis screening?
Emily A Kendall, Emily B Wong
Household- Versus Incentive-Based Contact Investigation for Tuberculosis in Rural South Africa: A Cluster-Randomized Trial
Hanrahan CF, Nonyane BAS, Lebina L, Mmolawa L, Siwelana T, West NS, Albaugh N, Martinson N, Dowdy DW.
Number Needed to Screen for Tuberculosis Disease Among Children: A Systematic Review
Robsky KO, Chaisson LH, Naufal F, Delgado-Barroso P, Alvarez-Manzo HS, Golub JE, Shapiro AE, Salazar-Austin N.
Mutations in Rv0678 Reduce Susceptibility of Mycobacterium tuberculosis to the DprE1 Inhibitor TBA-7371
Almeida DV, Converse PJ, Nuermberger EL.
An analytic feasibility study of the BD MAX™ MDR-TB assay for testing of non-sputum specimens for detection of the Mycobacterium tuberculosis complex (MTBC) and isoniazid (INH) and rifampin (RIF) resistance
Armstrong D, Fisher S, Totten M, Parrish N.
Differentially culturable tubercle bacteria as a measure of tuberculosis treatment response
Peters JS, McIvor A, Papadopoulos AO, Masangana T, Gordhan BG, Waja Z, Otwombe K, Letutu M, Kamariza M, Sterling TR, Bertozzi CR, Martinson NA, Kana ...
Pharmacokinetic analysis of linezolid for multidrug resistant tuberculosis at a tertiary care centre in Mumbai, India
Resendiz-Galvan JE, Arora PR, Abdelwahab MT, Udwadia ZF, Rodrigues C, Gupta A, Denti P, Ashavaid TF, Tornheim JA. Pharmacokinetic analysis of linezolid for multidrug resistant ...
Tuberculosis, Wildfires, and Case-crossover Studies: An Epidemiological Trifecta?
Checkley W. Tuberculosis, Wildfires, and Case-crossover Studies: An Epidemiological Trifecta? Am J Respir Crit Care Med. 2023 Feb 1;207(3):242-243. doi: 10.1164/rccm.202210-1936ED. PMID: 36315435; PMCID: PMC9896637.
Multicomponent strategy with decentralised molecular testing for tuberculosis in Uganda: a cost and cost-effectiveness analysis
Thompson RR, Nalugwa T, Oyuku D, Tucker A, Nantale M, Nakaweesa A, Musinguzi J, Reza TF, Zimmer AJ, Ferguson O, Turyahabwe S, Joloba M, Cattamanchi ...
Dynamic 18F-Pretomanid PET imaging in animal models of TB meningitis and human studies
Mota F, Ruiz-Bedoya CA, Tucker EW, Holt DP, De Jesus P, Lodge MA, Erice C, Chen X, Bahr M, Flavahan K, Kim J, Brosnan MK, ...
Characterising cause of death among people treated for drug-susceptible TB in India
Cox SR, Padmapriyadarsini C, Mave V, Seth B, Thiruvengadam K, Gaikwad S, Sahasrabudhe TR, Sane M, Tornheim JA, Shrinivasa BM, Lokhande R, Barthwal MS, Shivakumar ...
Transcriptional Analysis for Tuberculosis in Pregnant Women From the PRegnancy Associated Changes In Tuberculosis Immunology (PRACHITi) Study
Mathad JS, Queiroz ATL, Bhosale R, Alexander M, Naik S, Kulkarni V, Andrade BB, Gupta A. Transcriptional Analysis for Tuberculosis in Pregnant Women From the ...
Infectious and clinical tuberculosis trajectories: Bayesian modeling with case finding implications
Theresa S Ryckman, David W Dowdy , Emily A Kendall
Disadvantage and the Experience of Treatment for Multidrug-Resistant Tuberculosis (MDR-TB)
SSM Qual Res Health. 2022 Dec;2:100042. Taylor HA, Dowdy DW, Searle AR, Stennett AL, Dukhanin V, Zwerling AA, Merritt MW.
Cost and Cost-Effectiveness of a Digital Adherence Technology for Tuberculosis Treatment Support in Uganda
Value Health. 2022 Jun;25(6):924-930. Thompson RR, Kityamuwesi A, Kuan A, Oyuku D, Tucker A, Ferguson O, Kunihira Tinka L, Crowder R, Turyahabwe S, Cattamanchi A, ...
Ending tuberculosis in a post-COVID-19 world: a person-centred, equity-oriented approach.
Lancet Infect Dis. 2022 Aug 10:S1473-3099(22)00500-X. doi: 10.1016/S1473-3099(22)00500-X. Epub ahead of print. Ryckman T, Robsky K, Cilloni L, Zawedde-Muyanja S, Ananthakrishnan R, Kendall EA, Shrestha ...
Comparative assessment of the cost-effectiveness of Tuberculosis (TB) active case-finding interventions: A systematic analysis of TB REACH wave 5 projects
PLoS One. 2022 Sep 26;17(9):e0270816. Gomes I, Dong C, Vandewalle P, Khan A, Creswell J, Dowdy D, Sohn H.
Quantifying Mycobacterium tuberculosis transmission dynamics across global settings: a systematic analysis
Am J Epidemiol. 2022 Oct 13:kwac181. doi: 10.1093/aje/kwac181. Epub ahead of print. Smith J, Cohen T, Dowdy D, Shrestha S, Gandhi NR, Hill AN.
Analyzing Pragmatic Trials to Inform Cost-Effectiveness Analyses
Value Health. 2022 Oct 29:S1098-3015(22)04688-5. Dowdy DW, Thompson RR, Kityamuwesi A, Crowder R, Cattamanchi A, Katamba A, Sohn H.
Tuberculosis treatment adherence in the era of COVID-19.”
BMC Infect Dis. 2022 Oct 26;22(1):800. doi: 10.1186/s12879-022-07787-4. PMID: 36289485; PMCID: PMC9607764. Lippincott CK, Perry A, Munk E, Maltas G, Shah M.
Tuberculosis Epidemiologic Studies Consortium. Evaluation of the Latent Tuberculosis Care Cascade Among Public Health Clinics in the United States
Clin Infect Dis. 2022 Nov 14;75(10):1792-1799. doi: 10.1093/cid/ciac248. PMID: 35363249. Holzman SB, Perry A, Saleeb P, Pyan A, Keh C, Salcedo K, Narita M, Ahmed ...
Diagnostic biomarkers for active tuberculosis: progress and challenges
EMBO Mol Med. 2022 Oct 31;e14088. doi: 10.15252/emmm.202114088 Betânia M F Nogueira # 1 2 3, Sonya Krishnan # 4, Beatriz Barreto-Duarte 3 5 6 ...
An intranasal stringent response vaccine targeting dendritic cells as a novel adjunctive therapy against tuberculosis
Front Immunol. 2022 Sep 16;13:972266. doi: 10.3389/fimmu.2022.972266. eCollection 2022. Styliani Karanika 1 2, James T Gordy 3, Pranita Neupane 1 2, Theodoros Karantanos 4, Jennie ...